MedTrace Logo

Tushirikiane HIV-self Testing Intervention With Urban Refugee Youth in Kampala, Uganda

NCT04504097 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 454

Last updated 2021-12-28

No results posted yet for this study

Summary

HIV is the leading cause of death for adolescents and young people (AYP) in sub-Saharan Africa (SSA). Uganda hosts 1.3 million refugees/displaced persons, and more than 80,000 live in Kampala, most in slums, yet little is known of HIV testing and prevention needs with displaced/refugee AYP living in Kampala's slums. This study aims to develop, implement and evaluate an oral HIV-self testing (HIVST) intervention with displaced/refugee AYP aged 16- 24 in Kampala. HIVST is acceptable and properly used with AYP in other SSA regions, yet there are knowledge gaps regarding the best way to link HIVST to HIV care. This study aims to explore how m-health (healthcare delivered on mobile-phones), congruent with how AYP learn and socialize, can improve linkage to care with HIVST. This trial focuses on implementing a cluster randomized trial with displaced/refugee AYP aged 16-24 living in informal settlements in Kampala (Arm1: HIVST; Arm 2: HIVST + m-health; Arm 3: standard of care). The study will assess changes in HIV testing practices, HIV status knowledge, and linkage to HIV prevention and care between the 3 arms.

Conditions

  • HIV/AIDS
  • HIV Infections
  • Knowledge, Attitudes, Practice

Interventions

BEHAVIORAL

m-Health

Participants receive a weekly bidirectional text message (SMS) asking how they are doing. They are requested to reply fine, or not fine, in which case they will be contacted with support by a peer navigator. If they do not reply to the message within the specified timeframe a peer navigator will follow up with them.

DIAGNOSTIC_TEST

HIV self-testing

Participants will receive HIVST kits so that they can perform their HIV testing.

Sponsors & Collaborators

  • University of Toronto

    lead OTHER

Principal Investigators

  • Carmen Logie, PhD · University of Toronto, Canada

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-13
Primary Completion
2021-08-20
Completion
2021-09-20

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04504097 on ClinicalTrials.gov